Johnson & Johnson Stock News

Johnson & Johnson announced on November 12, 2021, that it is planning to separate its Consumer Health Business and create a new publicly traded Consumer Health Company. The press release states that the planned separation is expected to provide enhanced operational performance, drive growth, and unlock significant value. By: Knobbe Martens

Amid the surge of the Omicron variant of COVID-19, Grand Care Pharmacy in Maspeth is ready to serve the community. “At Grand Care Pharmacy, we are giving out booster shots to eligible people of all ages and communities,” said Dr. Trevor Latchminarain, pharmacist and owner at Grand Care Pharmacy. “We vaccinate approximately 60 to 80 patients daily with the booster shots. We are so happy to see that so many people have confidence in the vaccine, while at the same time ensuring that our communities are staying safe.” Latchminarain says patients have been eager to get their booster shots and the pharmacy has been getting positive feedback from patients. “The only requirement for getting the booster shot is ensuring that you are within the eligible time frame to obtain it,” Latchminarain says. “If you received two doses of Pfizer or Moderna, you would need to wait six months after your last dose. If you were vaccinated with Johnson & Johnson, you will need to wait two months from your last dose.” A 2009 graduate of the St.

Johnson & Johnson (NYSE:JNJ) price closed higher on Tuesday, December 07, jumping 0.26% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

As of Dec. 2, 5,224,655 worldwide have died from COVID-19, and the numbers only continue to rise. At first, vaccines seemed to be a light at the end of the tunnel. However, doses of Pfizer, Moderna and Johnson & Johnson, were not a cure-all. In the United States especially, many people opted out of… The post Social Determinants of Health and COVID-19 Vaccine Hesitancy in Marginalized Groups appeared first on The Daily Utah Chronicle .

The Mastercard Foundation and Africa CDC jointly announced that 756,000 Johnson & Johnson vaccines purchased under the Saving Lives and Livelihoods initiative have landed in Uganda and are set for distribution. The shipment is part of a first tranche of vaccines to be delivered under the initiative. Through Saving Lives and Livelihoods, the Mastercard Foundation [] The post Mastercard Foundation, Africa CDC deliver 756,000 Johnson & Johnson vaccine doses to Uganda appeared first on Nile Post .

Minnesota moved another step closer this week to unlocking roughly $300 million from a settlement with Johnson & Johnson and the three major U.S. drug distributors in connection to the nations opioid painkiller addiction crisis. Attorney General Keith Ellison announced Monday that the state had reached an agreement with Minnesota counties and cities on how []

Boenning & Scattergood Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,782 shares of the companys stock after selling 543 shares during the quarter. Johnson & Johnson makes up about []

Gateway Investment Advisers LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 754,383 shares of the companys stock after selling 2,371 shares during the period. Johnson & Johnson accounts for 1.3% []

Ontario announced last week that a limited supply of Johnson & Johnson viral-vector vaccines would be available to those who cannot receive the mRNA vaccine due to contraindications or those who are entirely unvaccinated. In the news release the province sent out, it was noted that individuals would need to call their local public health []

DUBLIN--(BUSINESS WIRE)--The "Dementia - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com''s offering. The clinical trial report provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia . The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by re

DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye

Janssen Pharmaceutical , a unit of Johnson & Johnson (NYSE: JNJ ), announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate. J&J shared top-line findings from the Phase 2b trial, revealing it hit its primary endpoint by linking the vaccine to 80% efficacy against confirmed RSV-associated lower respiratory tract disease. At that time, Full story available on Benzinga.com

LS Investment Advisors LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, HoldingsChannel reports. The firm owned 19,035 shares of the companys stock after buying an additional 380 shares during the quarter. LS Investment Advisors LLCs holdings in Johnson & Johnson were worth $3,074,000 at the end []